title: The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.
authors.forename: Jitka
authors.initials: J
authors.lastname: Malcikova
authors.forename: Filip
authors.initials: F
authors.lastname: Razga
authors.forename: Tomas
authors.initials: T
authors.lastname: Jurcek
authors.forename: Dana
authors.initials: D
authors.lastname: Dvorakova
authors.forename: Daniela
authors.initials: D
authors.lastname: Zackova
authors.forename: Martina
authors.initials: M
authors.lastname: Toskova
authors.forename: Ludmila
authors.initials: L
authors.lastname: Sebejova
authors.forename: Jana
authors.initials: J
authors.lastname: Smardova
authors.forename: Alexandra
authors.initials: A
authors.lastname: Oltova
authors.forename: Gabriela
authors.initials: G
authors.lastname: Vankova
authors.forename: Lenka
authors.initials: L
authors.lastname: Jurackova
authors.forename: Martin
authors.initials: M
authors.lastname: Trbusek
authors.forename: Sarka
authors.initials: S
authors.lastname: Pospisilova
authors.forename: Jiri
authors.initials: J
authors.lastname: Mayer
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Racil
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002869:Chromosome Aberrations; D003062:Codon; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; C581634:BCR-ABL1 fusion protein, human; D003062:Codon; D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl